While new diagnoses of diabetes in adults have slowed in recent years, the pandemic may reverse this trend. Physicians, payers, and pharmaceutical companies all can play a part in mitigating the long-term effects on persons with diabetes. Precision’s Cynthia Miller details how these stakeholders can collaborate to mitigate future damage.
Co-Founder and CEO of Precision Medicine Group Mark Clein sat down with CareTalk hosts John Driscoll and David E. Williams at HLTH Boston 2021 to discuss the game changing impact of precision medicine on treatments and patient outcomes.
In the midst of the pandemic uncertainties, organizations are continuing their quest for value-based care. Precision’s Elizabeth Oyekan and Dominic Galante discuss who will be the next generation access decision makers to successfully take the Triple Aim premise of value-based care, couple it with lessons learned from the pandemic, scale it up, and sustain success over time to make a palpable difference in the US healthcare system.
Quantitative studies are the gold standard for establishing causality and drawing conclusions that can be generalized beyond the population studied. However, quantitative research methods also often lack contextual considerations and perspectives that can be further informed by qualitative approaches.
High prescription drug prices continue to be of concern at the federal level. Despite proposed changes to drug pricing policy by the administration and HHS, industry experts question whether any significant changes will occur in the near future. Precision’s Ryan Cox and Erin Lopata weigh in on the factors contributing to the uncertainty about drug policy pricing changes.
Specialty drugs make up the bulk of the pharma pipeline. These drugs continue to come onto the market with higher and higher price tags, so employers should become more familiar with these therapies in order to properly manage them. Precision’s Erin Lopata and Jorge Font weigh in on the other considerations beyond cost that employers need to know for managing specialty drugs.
Several clinical scoring systems have gradually emerged for liver injury diagnosis, but certain serious inherent deficiencies currently limit their predictive value. Precision’s Anuj Mubayi and co-author Aditi Ghosh report on their first of its kind study to use mathematical modeling to provide an accurate novel prognosis method to improve tools for diagnosis and clinical management of drug-induced acute liver injury and heart-attack-influenced ischaemic hepatitis liver injury.
With drug pricing becoming a hot-button issue in recent years, the spotlight has focused on cost effectiveness models as a means of reducing health care spending, and pharmaceutical spending in particular. Precision’s Jacquelyn Chou argues that the current cost effectiveness model is too narrow, and identifies additional elements of value that should be included to provide a better voice for patients in the science, rather than serving as a cost-containment tool.
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision’s Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.
As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Precision’s Erin Lopata, Christopher Terrone and Ami Gopalan and their co-authors review the results of a PRECISIONvalue and AMCP survey with payer, provider, and employer decision makers about their experiences and activities in the orphan disease space, including tactics to manage affordability of drugs to treat orphan diseases.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
